These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20883512)

  • 1. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).
    Shah DP; Baez-Escudero JL; Weisberg IL; Beshai JF; Burke MC
    Pacing Clin Electrophysiol; 2012 Mar; 35(3):e62-4. PubMed ID: 20883512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome.
    Shimizu W; Ohe T; Kurita T; Kawade M; Arakaki Y; Aihara N; Kamakura S; Kamiya T; Shimomura K
    J Am Coll Cardiol; 1995 Nov; 26(5):1299-309. PubMed ID: 7594047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.
    Doshi D; Morrow JP
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S46-52. PubMed ID: 19898288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine maintained sinus rhythm in a patient with refractory symptomatic atrial fibrillation.
    Sossalla S; Sohns C; Seegers J; Lüthje L; Vollmann D; Zabel M
    Cardiovasc Ther; 2013 Oct; 31(5):303-6. PubMed ID: 23205928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.
    Carvas M; Nascimento BC; Acar M; Nearing BD; Belardinelli L; Verrier RL
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):286-91. PubMed ID: 20075744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective: does ranolazine have potential for the treatment of atrial fibrillation?
    Hancox JC; Doggrell SA
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1465-74. PubMed ID: 21105855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiarrhythmic effects of ranolazine.
    Foster NJ; Haines DE
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S38-45. PubMed ID: 19898287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8).
    Jacobs A; Knight BP; McDonald KT; Burke MC
    Heart Rhythm; 2006 Aug; 3(8):967-70. PubMed ID: 16876748
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
    Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
    J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic properties of ranolazine--from bench to bedside.
    Tzeis S; Andrikopoulos G
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome.
    Gao Y; Xue X; Hu D; Liu W; Yuan Y; Sun H; Li L; Timothy KW; Zhang L; Li C; Yan GX
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):614-22. PubMed ID: 23580742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation.
    Verrier RL; Kumar K; Nieminen T; Belardinelli L
    Europace; 2013 Mar; 15(3):317-24. PubMed ID: 23220484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine for the prevention or treatment of atrial fibrillation: a systematic review.
    Dagres N; Iliodromitis EK; Lekakis JP; Simitsis P; Karatzas D; Rallidis LS; Simeonidou E; Anastasiou-Nana M
    J Cardiovasc Med (Hagerstown); 2014 Mar; 15(3):254-9. PubMed ID: 24662415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A focus on antiarrhythmic properties of ranolazine.
    Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
    Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
    Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
    Cingolani E; Lepor NE; Singh BN
    Rev Cardiovasc Med; 2011; 12(3):136-42. PubMed ID: 22080924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ranolazine for rhythm control in an elderly patient with paroxysmal atrial fibrillation.
    Santillo E; Migale M; Postacchini D; Fallavollita L; Marini L; Balestrini F
    Clin Ter; 2014; 165(2):e166-9. PubMed ID: 24770828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug therapy of tachycardiac arrhythmias].
    Bender F
    Verh Dtsch Ges Kreislaufforsch; 1969; 35():97-105. PubMed ID: 4191388
    [No Abstract]   [Full Text] [Related]  

  • 20. [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
    Trappe HJ; Pfitzner P
    Med Klin (Munich); 1996 Oct; 91(10):617-25. PubMed ID: 9019638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.